{"gene":"TNF","run_date":"2026-06-10T10:51:55","timeline":{"discoveries":[{"year":2008,"finding":"TNF-alpha induces two distinct caspase-8 activation pathways: (1) cycloheximide co-treatment promotes caspase-8 activation by eliminating c-FLIP, independent of RIPK1; (2) Smac mimetic triggers autodegradation of cIAP1/2, releasing RIPK1 from the TNF receptor complex to form a caspase-8-activating complex consisting of RIPK1, FADD, and caspase-8, a process requiring CYLD (a RIPK1 K63 deubiquitinating enzyme).","method":"Cell-based signaling assays, pharmacological inhibition (cycloheximide, Smac mimetic), genetic manipulation of cIAP1/2, RIPK1, CYLD, and c-FLIP","journal":"Cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal genetic and pharmacological approaches in a single rigorous study, pathway placement confirmed","pmids":["18485876"],"is_preprint":false},{"year":2000,"finding":"TNF-alpha acts as a homotrimer that binds to either TNFR1 (55 kDa) or TNFR2 (75 kDa); crystal structures of TNF-alpha, TNF-beta, ectodomain of TNFR1, and the TNF-beta/sTNFR-1 complex have been determined, defining structure-function relationships including cysteine-rich extracellular repeat domains on receptors.","method":"X-ray crystallography, structural biology","journal":"Microscopy research and technique","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structures solved and replicated across multiple studies cited in review","pmids":["10891884"],"is_preprint":false},{"year":2010,"finding":"Transmembrane TNF-alpha (tmTNF-alpha) acts as a bipolar molecule: it transmits forward signals as a ligand by binding TNFR1/TNFR2 on target cells, and also acts as a receptor transmitting reverse (outside-to-inside) signals back to the producing cell upon binding of its native receptors.","method":"Cell-based signaling assays with transmembrane vs. soluble TNF-alpha constructs; functional differentiation from soluble form via receptor binding studies","journal":"Rheumatology (Oxford, England)","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — review summarizing accumulated experimental evidence from multiple studies, but no single primary experiment described in abstract","pmids":["20194223"],"is_preprint":false},{"year":2010,"finding":"Transmembrane TNF-alpha is cleaved from the cell surface by TNF-alpha-converting enzyme (TACE/ADAM17) to generate the soluble form of TNF-alpha.","method":"Biochemical cleavage assays; metalloprotease inhibition studies","journal":"Rheumatology (Oxford, England)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — established mechanism summarized in review, supported by multiple prior experimental studies","pmids":["20194223"],"is_preprint":false},{"year":1995,"finding":"Matrix metalloproteinases (MMPs) — including stromelysin, matrilysin, collagenase, and gelatinases — can cleave a recombinant pro-TNF substrate to yield mature TNF-alpha in vitro; broad-spectrum MMP inhibitors prevent processing of the TNF precursor and reduce blood TNF levels after endotoxin administration in rats.","method":"In vitro cleavage assay with purified MMPs and recombinant pro-TNF substrate; MMP inhibitors in vivo (rat endotoxin model)","journal":"Journal of leukocyte biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstitution with purified enzymes plus in vivo pharmacological validation","pmids":["7759957"],"is_preprint":false},{"year":2005,"finding":"A small-molecule inhibitor of TNF-alpha promotes subunit disassembly of the trimeric cytokine by forming an intermediate complex with the intact trimer, accelerating subunit dissociation 600-fold and leading to a compound-dimer complex. X-ray crystallography revealed a single compound molecule displaces one subunit from the trimer.","method":"X-ray crystallography, biochemical dissociation kinetics assay, cell-based inhibition assay","journal":"Science","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structure plus in vitro reconstitution and kinetics, multiple orthogonal methods in one study","pmids":["16284179"],"is_preprint":false},{"year":2001,"finding":"TNF-alpha promotes oligodendrocyte progenitor proliferation and remyelination through TNFR2 (not TNFR1); mice lacking TNFR2 showed delayed remyelination and reduced pools of proliferating NG2+ oligodendrocyte progenitors and mature oligodendrocytes after cuprizone-induced demyelination.","method":"Genetic knockout mice (TNF-alpha-/-, TNFR1-/-, TNFR2-/-), histology, immunohistochemistry, electron microscopy, BrdU labeling","journal":"Nature neuroscience","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple receptor-specific knockout lines with morphometric and proliferation readouts","pmids":["11600888"],"is_preprint":false},{"year":1999,"finding":"TNF-alpha mediates insulin resistance through serine phosphorylation of IRS-1, impairing insulin receptor tyrosine phosphorylation signaling; TNF-alpha knockout obese mice showed approximately 2-fold increased insulin-stimulated tyrosine phosphorylation of the insulin receptor in muscle and adipose tissue compared to wild-type obese mice.","method":"TNF-alpha and TNF receptor knockout mice (ob/ob background, diet-induced obesity), glucose/insulin tolerance tests, phosphorylation assays","journal":"Experimental and clinical endocrinology & diabetes","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple receptor-specific knockout lines with biochemical phosphorylation readouts and metabolic phenotyping","pmids":["10320052"],"is_preprint":false},{"year":1998,"finding":"BRE protein was identified as a binding partner for the cytoplasmic/juxtamembrane domain of the p55 TNF receptor (TNFR1) via yeast two-hybrid screen and confirmed by in vitro biochemical pulldown with recombinant fusion proteins and co-immunoprecipitation in transfected mammalian cells; BRE specifically interacted with p55 TNFR but not p75 TNFR, Fas, or p75 neurotrophin receptor. Overexpression of BRE inhibited TNF-induced NF-κB activation.","method":"Yeast two-hybrid screen, in vitro pulldown with recombinant fusion proteins, co-immunoprecipitation, NF-κB reporter assay","journal":"FASEB journal","confidence":"High","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP plus in vitro pulldown plus functional NF-κB reporter, multiple orthogonal methods","pmids":["9737713"],"is_preprint":false},{"year":1996,"finding":"TNF-alpha activates the MAPK cascade in macrophages via sequential activation of MEKK and MEK1 in a c-Raf-1- and Raf-B-independent fashion downstream of CD120a (p55 TNFR); MEKK activity peaked within 30 seconds of TNF-alpha exposure, temporally preceding peak activation of p42mapk/ERK2.","method":"Kinase activity assays, temporal signaling analysis in mouse macrophages, pharmacological dissection","journal":"Immunobiology","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — kinase cascade assays in macrophages, single lab, single study","pmids":["8933152"],"is_preprint":false},{"year":2003,"finding":"In vivo TNF-alpha at sepsis-level doses transiently inhibits thrombus formation via iNOS-dependent generation of NO in the vessel wall; this antithrombotic effect requires iNOS (abolished in iNOS-deficient mice) and is not exerted directly on platelets. TNF receptor 1- and 2-deficient mice showed normal thrombogenesis in the presence of TNF-alpha.","method":"Intravital microscopy, iNOS-knockout and TNFR1/TNFR2-deficient mice, platelet function assays, bleeding time measurement","journal":"Journal of Clinical Investigation","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple genetic knockout lines plus intravital imaging, mechanistic pathway confirmed by receptor and enzyme deficiency","pmids":["14617760"],"is_preprint":false},{"year":1999,"finding":"TNF-alpha mediates corneal Langerhans cell migration through both TNFR1 (p55) and TNFR2 (p75) signaling; IL-1-induced LC migration is largely mediated by TNFR function, while TNF-alpha-induced LC migration is independent of IL-1 receptor I activity.","method":"Gene-targeted knockout mice (IL-1RI-/-, p55-/-, p75-/-, double p55/p75-/-), immunofluorescence migration assay, cytokine injection","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple receptor-specific knockout lines with quantitative migration assay and epistasis analysis","pmids":["10201952"],"is_preprint":false},{"year":2018,"finding":"iRhom2 regulates ADAM17-dependent shedding of TNF-alpha and HB-EGF; deficiency of iRhom2 simultaneously blocks TNF-alpha and EGFR (HB-EGF) signaling in the kidney, protecting against lupus nephritis without altering anti-dsDNA antibody production.","method":"iRhom2-knockout in Fcgr2b-/- lupus-prone mice, transcriptome profiling, pharmacological blockade of TNF-alpha and EGFR","journal":"Journal of Clinical Investigation","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic knockout with unbiased transcriptome profiling and orthogonal pharmacological validation","pmids":["29369823"],"is_preprint":false},{"year":2018,"finding":"Transmembrane TNF-alpha (tmTNF-alpha) mediates doxorubicin resistance in breast cancer cells through reverse signaling via the tmTNF-alpha/NTF-ERK-GST-π axis and tmTNF-alpha/NTF-NF-κB-mediated anti-apoptotic pathways; the intracellular domain of tmTNF-alpha is required, as overexpression of the N-terminal fragment (NTF) containing the intracellular domain was sufficient to induce resistance.","method":"tmTNF-alpha overexpression/knockdown, NTF mutant constructs, Western blot, xenograft mouse model","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — domain-specific mutants plus in vivo xenograft, single lab","pmids":["29559745"],"is_preprint":false},{"year":2019,"finding":"TNF-alpha directly induces RANKL mRNA expression in osteocytes through activation of MAPKs and NF-κB (p65 nuclear translocation), leading to enhanced osteoclastogenesis; MAPK inhibitors significantly decreased TNF-alpha-induced RANKL expression in osteocytes.","method":"Primary osteocyte isolation by FACS from Dmp1-Topaz mice, co-culture with TNFR-deficient osteoclast precursors, Western blot for MAPK phosphorylation, in vivo calvarial injection, TRAP staining","journal":"Frontiers in immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — primary cell isolation, receptor-deficient co-culture system, in vitro and in vivo validation with inhibitor confirmation","pmids":["31921183"],"is_preprint":false},{"year":2016,"finding":"RIPK1 serves as a scaffold protecting hepatocytes from TNF-alpha-triggered apoptosis; in mice lacking RIPK1 specifically in liver parenchymal cells (Ripk1LPC-KO), ConA-induced hepatitis leads to TNF-alpha-driven massive apoptotic cell death. RIPK1 kinase activity contributes to caspase-independent necrotic cell death.","method":"Conditional knockout mice (Ripk1LPC-KO) and RIPK1 kinase-dead knock-in mice (Ripk1K45A), concanavalin A hepatitis model, caspase activity assays","journal":"Cell death & disease","confidence":"High","confidence_rationale":"Tier 2 / Strong — two complementary genetic mouse models separating scaffold vs. kinase function, defined cellular phenotype","pmids":["27831558"],"is_preprint":false},{"year":2001,"finding":"TNF-alpha directly inhibits CD28 gene transcription in T cells by inactivating DNA-protein complex formation at two sequence motifs corresponding to the transcriptional initiator of the CD28 gene; nuclear extracts from TNF-alpha-treated cells failed to activate transcription from templates under control of the CD28 initiator sequences in in vitro transcription assays.","method":"Reporter gene assays, electrophoretic mobility shift assay (EMSA), in vitro transcription assay, T cell line/clone culture","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro transcription reconstitution plus EMSA plus reporter assay, multiple orthogonal methods","pmids":["11544310"],"is_preprint":false},{"year":2008,"finding":"TNF-alpha induces mitochondrial dysfunction in neurons through TNFR1 (not TNFR2), involving caspase-8 activation, decrease in mitochondrial membrane potential, and cytochrome c release from mitochondria into the cytosol; pre-treatment with TNFR1 antibody ameliorated neurotoxic effects.","method":"Mitochondrial function assays (basal respiration, ATP production), receptor-specific antibody blockade, caspase-8 activity assay, mitochondrial membrane potential measurement, cytochrome c subcellular fractionation","journal":"Journal of neurochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — receptor-specific blockade with multiple functional readouts, single lab","pmids":["25492727"],"is_preprint":false},{"year":2003,"finding":"TNF-alpha acts as a mitogen in skeletal muscle by activating satellite cells to enter the cell cycle (G1-to-S phase transition) through stimulation of serum response factor (SRF) binding to the serum response element (SRE) in the c-fos gene promoter and activation of early response gene expression.","method":"BrdU incorporation assay in primary myoblasts and adult mouse muscle (in vivo injection), SRF-SRE binding assay, reporter gene assay","journal":"American journal of physiology. Cell physiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro and in vivo BrdU assays plus SRF binding mechanism, single lab","pmids":["12711593"],"is_preprint":false},{"year":2015,"finding":"TNF-alpha suppresses multimerization and secretion of adiponectin by downregulating ER-resident chaperones ERO1-La, DsbA-L, and ERp44, impairing disulfide bond modification; TNF-alpha treatment enhanced the interaction between adiponectin and ERp44. PPARγ overexpression antagonized these effects by directly binding PPRE elements of ERO1-La and DsbA-L promoters.","method":"In vitro and in vivo adiponectin multimerization assays, Co-IP (adiponectin-ERp44 interaction), Western blot, ChIP assay for PPARγ binding","journal":"Endocrine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP plus ChIP plus functional rescue, single lab","pmids":["26407855"],"is_preprint":false},{"year":2014,"finding":"TNF-alpha promotes invasive growth by inducing MET receptor tyrosine kinase transcription via NF-κB; MET then sustains MEK/ERK activation and Snail accumulation leading to E-cadherin downregulation. TNF-alpha also induces HGF secretion by fibroblasts, creating a paracrine HGF/MET pro-invasive loop.","method":"MET-specific inhibitors (small molecules, antibodies, siRNA), NF-κB pathway analysis, Western blot for Snail and E-cadherin, invasion assays","journal":"Molecular oncology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple MET inhibition approaches plus mechanistic pathway dissection, single lab","pmids":["25306394"],"is_preprint":false},{"year":2001,"finding":"TNF-alpha inhibits 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2) activity and mRNA expression in LLC-PK1 cells via MEK/ERK and p38 MAPK pathways (not PKC), thereby enhancing glucocorticoid access to receptors; the effect was reversed by ERK inhibitor PD-098050, p38 inhibitor SB-202190, or PKA activator forskolin. Overexpression of MEK1 down-regulated 11β-HSD2 activity.","method":"Enzyme activity assays, mRNA quantification, kinase inhibitors, MEK1 overexpression, PKC inhibitor GF-109203X","journal":"FEBS letters","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological dissection plus MEK1 overexpression, multiple inhibitors tested, single lab","pmids":["11696370"],"is_preprint":false},{"year":2018,"finding":"TNF-alpha induces Drp1-mediated mitochondrial fragmentation in cardiomyocytes through activation of RhoA and the RhoA/ROCK pathway, which phosphorylates Drp1 at Ser616 and promotes its mitochondrial translocation; ROCK inhibitors (Y-27632 and fasudil) attenuated TNF-alpha-induced p-Drp1 Ser616, mitochondrial Drp1 accumulation, and mitochondrial fragmentation.","method":"Western blot for Drp1 and p-Drp1 Ser616, confocal microscopy for mitochondrial morphology, ROCK inhibitors, in vitro H9C2 cardiomyocytes","journal":"International journal of molecular medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological pathway dissection with morphological and biochemical readouts, single lab","pmids":["29336470"],"is_preprint":false},{"year":2016,"finding":"TNF-alpha downregulates CIDEC expression in human adipocytes through the MEK/ERK pathway by phosphorylating PPARγ and causing its nuclear export; constitutively active MEK1 mutant recapitulated TNF-alpha effects, and MEK/ERK inhibition prevented TNF-alpha-mediated CIDEC downregulation. Reporter assay confirmed direct reduction in CIDEC transcription.","method":"Selective kinase inhibitors, RNAi, constitutively active MEK1 mutant, immunofluorescence, subcellular fractionation, luciferase reporter assay","journal":"Obesity (Silver Spring)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple genetic/pharmacological perturbations plus reporter assay, single lab","pmids":["27062372"],"is_preprint":false},{"year":2008,"finding":"TNF-alpha activates Akt and ERK1/2 in premalignant keratinocytes through an atypical protein kinase C (aPKC, zeta/iota-lambda)-, NF-κB-, and hydroxyl radical-dependent pathway; aPKC peptide inhibitor abrogated TNF-alpha effects on Akt and ERK1/2 but increased p38 activation. Iron chelation (blocking OH radical formation) abolished Akt/ERK signaling.","method":"Specific peptide inhibitors for aPKC, NF-κB inhibitors, p38 inhibitors, iron chelator desferroxamine, phosphorylation assays in HaCaT cells","journal":"Experimental dermatology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple pathway inhibitors with defined signaling bifurcation, single lab","pmids":["18557926"],"is_preprint":false},{"year":2019,"finding":"Cortistatin (CST) competitively binds to both TNFR1 and TNFR2, suppressing TNF-alpha proinflammatory signaling; CST inhibits NF-κB pathway activation in osteoarthritis, and TNFR1/TNFR2 knockout mice implicated these receptors as required for CST's protective role.","method":"Co-immunoprecipitation, biotin-based solid-phase binding assay, Western blot, TNFR1/TNFR2-knockout mice, OA models","journal":"EBioMedicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal binding assays plus receptor-deficient mice, single lab","pmids":["30826358"],"is_preprint":false},{"year":2002,"finding":"TNF-alpha mediates skeletal muscle DNA fragmentation (apoptosis) during cancer cachexia; mice deficient in TNFR1 (p55) showed a markedly attenuated increase in muscle DNA fragmentation (2.1-fold vs. 9.8-fold in wild-type) upon Lewis lung carcinoma inoculation.","method":"TNF-alpha administration to rats, TNFR1 gene-deficient mice with Lewis lung carcinoma, DNA fragmentation (laddering) assay","journal":"British journal of cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — receptor-deficient mice with quantitative DNA fragmentation assay, single lab","pmids":["11953838"],"is_preprint":false},{"year":2020,"finding":"TNF-alpha stimulates expression of the histone acetyltransferase MOF in macrophages, and MOF acts as a coactivator of NF-κB-mediated inflammatory gene transcription; ChIP showed elevated H4K16 acetylation on inflammatory gene promoters in diabetic wound macrophages; etanercept (TNF-α inhibitor) treatment reduced MOF levels and improved diabetic wound healing.","method":"Myeloid-specific Mof-knockout mice (Lyz2Cre Moffl/fl), ChIP for H4K16ac, diet-induced obesity model, etanercept treatment","journal":"JCI insight","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — conditional knockout with ChIP and pharmacological validation, single lab","pmids":["32069267"],"is_preprint":false},{"year":2011,"finding":"TNF-alpha (TNFSF2) increases intestinal epithelial paracellular permeability via caspase-driven apoptosis and cell shedding (distinct from IFNγ mechanism which does not involve apoptosis); TNF-alpha also fundamentally alters intestinal epithelial morphogenesis through its pro-apoptotic effect. Infliximab and adalimumab blocked these effects.","method":"Three-dimensional intestinal epithelial cell culture system, permeability assays, caspase inhibition, anti-TNF antibody treatment, tight junction protein localization","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — 3D culture model with pharmacological rescue and comparative cytokine dissection, single lab","pmids":["21853060"],"is_preprint":false},{"year":2020,"finding":"TNF-alpha induces RUNX1 expression in retinal endothelial cells via JNK activation (not NF-κB or p38/MAPK), linking through Activator Protein 1 (AP-1) in a JNK-AP-1-RUNX1 regulatory feedback loop; JNK inhibitors also blocked high D-glucose-stimulated RUNX1 expression.","method":"TNF-α pathway inhibitors in HRMECs, Western blot, JNK/NF-κB/p38 inhibitors","journal":"FASEB journal","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — pathway inhibitor dissection, single lab, single study","pmids":["33135824"],"is_preprint":false}],"current_model":"TNF-alpha is a homotrimeric cytokine that signals through two receptors (TNFR1/p55 and TNFR2/p75); it is proteolytically shed from the membrane-anchored precursor by TACE/ADAM17 and matrix metalloproteinases, while the transmembrane form mediates bidirectional signaling. Upon receptor engagement, TNF-alpha activates NF-κB and MAPK cascades, and depending on cellular context and co-stimuli induces two mechanistically distinct caspase-8 activation pathways leading to apoptosis or necroptosis (via a RIPK1–FADD–caspase-8 complex regulated by cIAP1/2, CYLD, and c-FLIP), triggers mitochondrial dysfunction through TNFR1, drives osteoclastogenesis via osteocyte RANKL induction through MAPK/NF-κB, mediates insulin resistance through serine phosphorylation of IRS-1, promotes satellite cell proliferation in muscle via SRF/SRE activation, supports oligodendrocyte progenitor renewal through TNFR2, and exerts antithrombotic effects via iNOS-dependent NO generation in the vessel wall."},"narrative":{"mechanistic_narrative":"TNF-alpha is a homotrimeric cytokine that acts as a master regulator of inflammation, cell death, and tissue remodeling by engaging two distinct receptors, TNFR1 (p55) and TNFR2 (p75), each bearing cysteine-rich extracellular repeats that recognize the trimeric ligand [PMID:10891884]. It is synthesized as a transmembrane precursor that is proteolytically shed to release the soluble cytokine by the TACE/ADAM17 sheddase — itself dependent on iRhom2 — and, independently, by matrix metalloproteinases that process pro-TNF both in vitro and in vivo [PMID:20194223, PMID:29369823, PMID:7759957]. The transmembrane form is bidirectional, transmitting forward signals as a ligand and reverse (outside-to-inside) signals back into the producing cell [PMID:20194223]. A defining feature of TNF-alpha signaling is its control over caspase-8-dependent death: it engages two mechanistically distinct routes, one driven by loss of c-FLIP and independent of RIPK1, and a second in which cIAP1/2 autodegradation releases RIPK1 to assemble a CYLD-dependent RIPK1–FADD–caspase-8 death complex [PMID:18485876], with RIPK1 acting as a scaffold that protects cells from TNF-driven apoptosis while its kinase activity drives necrotic death [PMID:27831558]. Through TNFR1, TNF-alpha precipitates mitochondrial dysfunction and apoptotic tissue loss [PMID:25492727, PMID:11953838], whereas TNFR2 mediates regenerative outputs such as oligodendrocyte progenitor proliferation and remyelination [PMID:11600888]. TNF-alpha couples receptor engagement to NF-κB and MAPK cascades [PMID:8933152, PMID:9737713], driving osteocyte RANKL induction and osteoclastogenesis [PMID:31921183], metabolic disruption including IRS-1-mediated insulin resistance and suppression of adiponectin assembly [PMID:10320052, PMID:26407855], and pro-invasive and inflammatory transcriptional programs [PMID:25306394, PMID:32069267]. Receptor-blocking and pathway-modulating agents — including the trimer-disassembling small molecule, anti-TNF antibodies, and competitive ligands such as cortistatin — define multiple points at which this signaling can be intercepted [PMID:16284179, PMID:21853060, PMID:30826358].","teleology":[{"year":1995,"claim":"Established that mature soluble TNF-alpha can be liberated from its precursor by proteolytic processing, identifying matrix metalloproteinases as candidate sheddases controlling circulating TNF levels.","evidence":"In vitro cleavage of recombinant pro-TNF by purified MMPs and MMP-inhibitor blockade of TNF release in a rat endotoxin model","pmids":["7759957"],"confidence":"High","gaps":["Did not establish the dominant physiological sheddase versus ADAM17","No structural definition of the cleavage site"]},{"year":1996,"claim":"Defined how TNFR1 engagement is transduced into MAPK signaling, placing MEKK and MEK1 upstream of ERK independent of c-Raf-1/Raf-B.","evidence":"Temporal kinase activity assays and pharmacological dissection in mouse macrophages","pmids":["8933152"],"confidence":"Medium","gaps":["Single lab, single cell type","Direct receptor-to-MEKK linkage not biochemically reconstituted"]},{"year":1998,"claim":"Identified a receptor-proximal regulator by showing BRE binds the TNFR1 cytoplasmic domain and dampens TNF-induced NF-κB activation, providing receptor specificity at the signaling interface.","evidence":"Yeast two-hybrid, reciprocal Co-IP and in vitro pulldown, NF-κB reporter assay","pmids":["9737713"],"confidence":"High","gaps":["Mechanism by which BRE inhibits NF-κB not resolved","Physiological relevance in primary cells untested"]},{"year":1999,"claim":"Demonstrated receptor-specific physiological roles, linking TNFR1 to IRS-1 serine phosphorylation and insulin resistance, and both receptors to Langerhans cell migration.","evidence":"TNF-alpha and receptor knockout mice with phosphorylation/metabolic phenotyping and quantitative migration assays","pmids":["10320052","10201952"],"confidence":"High","gaps":["Kinase responsible for IRS-1 serine phosphorylation not identified","Receptor-specific contributions to migration not fully separated"]},{"year":2000,"claim":"Provided the structural basis for TNF-alpha action by defining the homotrimeric ligand and its receptor-binding architecture.","evidence":"X-ray crystal structures of TNF-alpha, TNF-beta, TNFR1 ectodomain, and a TNF-beta/sTNFR-1 complex","pmids":["10891884"],"confidence":"High","gaps":["No structure of full TNF-alpha/TNFR1 or TNFR2 signaling complexes described","Transmembrane form not structurally resolved"]},{"year":2001,"claim":"Extended TNF-alpha into transcriptional and enzymatic control, showing it represses CD28 transcription in T cells and inhibits 11β-HSD2 via MAPK pathways.","evidence":"EMSA, in vitro transcription and reporter assays in T cells; enzyme activity assays with MEK/ERK and p38 inhibitors in LLC-PK1 cells","pmids":["11544310","11696370"],"confidence":"High","gaps":["Transcription factors mediating CD28 repression not identified","Cell-type generality of 11β-HSD2 effect untested"]},{"year":2003,"claim":"Revealed context-dependent and even regenerative/protective outputs: TNF-alpha acts as a satellite-cell mitogen via SRF/SRE and exerts a transient iNOS-dependent antithrombotic effect in the vessel wall.","evidence":"BrdU and SRF-SRE binding assays in myoblasts; intravital microscopy in iNOS- and TNFR-deficient mice","pmids":["12711593","14617760"],"confidence":"High","gaps":["Receptor mediating satellite-cell mitogenesis not defined","Cell type generating iNOS-dependent NO not pinpointed"]},{"year":2008,"claim":"Resolved the bifurcation of TNF-alpha-induced caspase-8 activation into a c-FLIP-loss/RIPK1-independent route and a cIAP1/2-degradation/CYLD-dependent RIPK1–FADD–caspase-8 complex, and linked TNFR1 to mitochondrial apoptosis.","evidence":"Orthogonal genetic/pharmacological dissection of cIAP1/2, RIPK1, CYLD, c-FLIP; mitochondrial function and cytochrome c release assays with receptor blockade","pmids":["18485876","25492727"],"confidence":"High","gaps":["Switch determinants between apoptosis and necroptosis not fully defined","Mitochondrial study limited to a single lab/neuronal model"]},{"year":2010,"claim":"Defined the transmembrane TNF-alpha biology, establishing it as a bidirectional signaling molecule and confirming ADAM17/TACE as the sheddase generating soluble TNF.","evidence":"Review of transmembrane vs soluble construct signaling and metalloprotease cleavage studies","pmids":["20194223"],"confidence":"Medium","gaps":["Reverse-signaling intracellular effectors not enumerated","Review-level synthesis rather than single primary experiment"]},{"year":2016,"claim":"Separated RIPK1 scaffold from kinase functions in vivo, showing the scaffold protects hepatocytes from TNF-driven apoptosis while kinase activity drives necrosis.","evidence":"Conditional Ripk1 knockout and kinase-dead knock-in mice in ConA hepatitis","pmids":["27831558"],"confidence":"High","gaps":["Substrate landscape of RIPK1 kinase activity not mapped","Tissue specificity beyond liver untested"]},{"year":2018,"claim":"Connected TNF shedding to disease via iRhom2-controlled ADAM17 activity and revealed transmembrane TNF reverse signaling as a driver of chemoresistance.","evidence":"iRhom2-knockout lupus-prone mice with transcriptome profiling; NTF domain mutants and xenografts for tmTNF reverse signaling","pmids":["29369823","29559745"],"confidence":"Medium","gaps":["Direct intracellular partners of the tmTNF intracellular domain not identified","iRhom2 specificity for TNF versus other substrates not exhaustive"]},{"year":2019,"claim":"Linked TNF-alpha to bone resorption through direct osteocyte RANKL induction and identified cortistatin as a competitive antagonist at both receptors.","evidence":"Primary osteocyte/osteoclast co-culture with MAPK inhibitors and in vivo calvarial assays; reciprocal binding assays and receptor-knockout OA models","pmids":["31921183","30826358"],"confidence":"Medium","gaps":["Relative receptor contribution to RANKL induction not parsed","Cortistatin binding stoichiometry/affinity not quantified"]},{"year":2020,"claim":"Expanded TNF-alpha's transcriptional reach by identifying MOF-driven H4K16 acetylation as an NF-κB coactivation mechanism and JNK-AP-1-RUNX1 as a distinct endothelial circuit.","evidence":"Myeloid-specific Mof-knockout mice with ChIP and etanercept rescue; pathway-inhibitor dissection in retinal endothelial cells","pmids":["32069267","33135824"],"confidence":"Medium","gaps":["Generality of MOF coactivation across inflammatory contexts untested","JNK-AP-1-RUNX1 loop shown by inhibitors only, single lab"]},{"year":null,"claim":"How cellular context selects among TNF-alpha's divergent outputs — NF-κB survival, apoptosis, necroptosis, regeneration, and metabolic disruption — through a shared receptor set remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unifying quantitative model of TNFR1 versus TNFR2 output selection","Structural basis of differential receptor complex assembly not defined","Determinants partitioning the RIPK1 complex toward apoptosis versus necroptosis incompletely mapped"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[1,2,6]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[0,2,17]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[8,25]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[2,3,13]},{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[3,4]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,9,8]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[0,15,17,26]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[11,27]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[3,4,12]}],"complexes":["RIPK1-FADD-caspase-8 complex"],"partners":["TNFRSF1A","TNFRSF1B","ADAM17","RHBDF2","BRE","RIPK1","CST"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P01375","full_name":"Tumor necrosis factor","aliases":["Cachectin","TNF-alpha","Tumor necrosis factor ligand superfamily member 2","TNF-a"],"length_aa":233,"mass_kda":25.6,"function":"Cytokine that binds to TNFRSF1A/TNFR1 and TNFRSF1B/TNFBR. It is mainly secreted by macrophages and can induce cell death of certain tumor cell lines. It is potent pyrogen causing fever by direct action or by stimulation of interleukin-1 secretion and is implicated in the induction of cachexia, Under certain conditions it can stimulate cell proliferation and induce cell differentiation. Impairs regulatory T-cells (Treg) function in individuals with rheumatoid arthritis via FOXP3 dephosphorylation. Up-regulates the expression of protein phosphatase 1 (PP1), which dephosphorylates the key 'Ser-418' residue of FOXP3, thereby inactivating FOXP3 and rendering Treg cells functionally defective (PubMed:23396208). Key mediator of cell death in the anticancer action of BCG-stimulated neutrophils in combination with DIABLO/SMAC mimetic in the RT4v6 bladder cancer cell line (PubMed:16829952, PubMed:22517918, PubMed:23396208). Induces insulin resistance in adipocytes via inhibition of insulin-induced IRS1 tyrosine phosphorylation and insulin-induced glucose uptake. Induces GKAP42 protein degradation in adipocytes which is partially responsible for TNF-induced insulin resistance (By similarity). Plays a role in angiogenesis by inducing VEGF production synergistically with IL1B and IL6 (PubMed:12794819). Promotes osteoclastogenesis and therefore mediates bone resorption (By similarity) The TNF intracellular domain (ICD) form induces IL12 production in dendritic cells","subcellular_location":"Secreted","url":"https://www.uniprot.org/uniprotkb/P01375/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/TNF","classification":"Not Classified","n_dependent_lines":5,"n_total_lines":1208,"dependency_fraction":0.0041390728476821195},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/TNF","total_profiled":1310},"omim":[{"mim_id":"621524","title":"WD REPEAT- AND SOCS BOX-CONTAINING PROTEIN 2; WSB2","url":"https://www.omim.org/entry/621524"},{"mim_id":"621234","title":"ICHAD SYNDROME; ICHAD","url":"https://www.omim.org/entry/621234"},{"mim_id":"621142","title":"CHROMOSOME 15 OPEN READING FRAME 39; C15ORF39","url":"https://www.omim.org/entry/621142"},{"mim_id":"621096","title":"IMMUNODEFICIENCY 132B; IMD132B","url":"https://www.omim.org/entry/621096"},{"mim_id":"621030","title":"AUTOINFLAMMATION, PANNICULITIS, AND DERMATOSIS SYNDROME, AUTOSOMAL DOMINANT; AIPDSA","url":"https://www.omim.org/entry/621030"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in some","driving_tissues":[{"tissue":"bone marrow","ntpm":19.9},{"tissue":"lymphoid tissue","ntpm":6.1}],"url":"https://www.proteinatlas.org/search/TNF"},"hgnc":{"alias_symbol":["TNFSF2","DIF","TNF-alpha"],"prev_symbol":["TNFA"]},"alphafold":{"accession":"P01375","domains":[{"cath_id":"2.60.120.40","chopping":"86-231","consensus_level":"high","plddt":96.5962,"start":86,"end":231},{"cath_id":"1.20.5","chopping":"29-58","consensus_level":"medium","plddt":83.061,"start":29,"end":58}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P01375","model_url":"https://alphafold.ebi.ac.uk/files/AF-P01375-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P01375-F1-predicted_aligned_error_v6.png","plddt_mean":84.56},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=TNF","jax_strain_url":"https://www.jax.org/strain/search?query=TNF"},"sequence":{"accession":"P01375","fasta_url":"https://rest.uniprot.org/uniprotkb/P01375.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P01375/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P01375"}},"corpus_meta":[{"pmid":"18485876","id":"PMC_18485876","title":"TNF-alpha induces two distinct caspase-8 activation pathways.","date":"2008","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/18485876","citation_count":1138,"is_preprint":false},{"pmid":"11600888","id":"PMC_11600888","title":"TNF alpha promotes proliferation of oligodendrocyte progenitors and remyelination.","date":"2001","source":"Nature neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/11600888","citation_count":823,"is_preprint":false},{"pmid":"10891884","id":"PMC_10891884","title":"TNF alpha and the TNF receptor superfamily: structure-function relationship(s).","date":"2000","source":"Microscopy research and technique","url":"https://pubmed.ncbi.nlm.nih.gov/10891884","citation_count":806,"is_preprint":false},{"pmid":"20194223","id":"PMC_20194223","title":"Transmembrane TNF-alpha: structure, function and interaction with anti-TNF agents.","date":"2010","source":"Rheumatology (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/20194223","citation_count":655,"is_preprint":false},{"pmid":"23685857","id":"PMC_23685857","title":"TNF-α signalling and inflammation: interactions between old acquaintances.","date":"2013","source":"Inflammation research : official journal of the European Histamine Research Society ... [et al.]","url":"https://pubmed.ncbi.nlm.nih.gov/23685857","citation_count":653,"is_preprint":false},{"pmid":"19118493","id":"PMC_19118493","title":"Role of TNF-alpha in vascular dysfunction.","date":"2009","source":"Clinical science (London, England : 1979)","url":"https://pubmed.ncbi.nlm.nih.gov/19118493","citation_count":554,"is_preprint":false},{"pmid":"12951580","id":"PMC_12951580","title":"Anti-TNF-alpha therapies: the next generation.","date":"2003","source":"Nature reviews. Drug discovery","url":"https://pubmed.ncbi.nlm.nih.gov/12951580","citation_count":452,"is_preprint":false},{"pmid":"16284179","id":"PMC_16284179","title":"Small-molecule inhibition of TNF-alpha.","date":"2005","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/16284179","citation_count":426,"is_preprint":false},{"pmid":"1581770","id":"PMC_1581770","title":"TNF alpha--a pivotal role in rheumatoid arthritis?","date":"1992","source":"British journal of rheumatology","url":"https://pubmed.ncbi.nlm.nih.gov/1581770","citation_count":356,"is_preprint":false},{"pmid":"24592264","id":"PMC_24592264","title":"Classical and Paradoxical Effects of TNF-α on Bone Homeostasis.","date":"2014","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/24592264","citation_count":340,"is_preprint":false},{"pmid":"11431443","id":"PMC_11431443","title":"TNF-alpha and TNF-alpha receptor-1 in the retina of normal and glaucomatous eyes.","date":"2001","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/11431443","citation_count":339,"is_preprint":false},{"pmid":"18629684","id":"PMC_18629684","title":"Insulin resistance associated to obesity: the link TNF-alpha.","date":"2008","source":"Archives of physiology and biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18629684","citation_count":333,"is_preprint":false},{"pmid":"10355025","id":"PMC_10355025","title":"The role of TNF alpha in adipocyte metabolism.","date":"1999","source":"Seminars in cell & developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/10355025","citation_count":326,"is_preprint":false},{"pmid":"15146098","id":"PMC_15146098","title":"The role of TNF-alpha in insulin resistance.","date":"2004","source":"Endocrine","url":"https://pubmed.ncbi.nlm.nih.gov/15146098","citation_count":308,"is_preprint":false},{"pmid":"10320052","id":"PMC_10320052","title":"Mechanisms of TNF-alpha-induced insulin resistance.","date":"1999","source":"Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","url":"https://pubmed.ncbi.nlm.nih.gov/10320052","citation_count":303,"is_preprint":false},{"pmid":"20173393","id":"PMC_20173393","title":"TNF-alpha and obesity.","date":"2010","source":"Current directions in autoimmunity","url":"https://pubmed.ncbi.nlm.nih.gov/20173393","citation_count":252,"is_preprint":false},{"pmid":"10891887","id":"PMC_10891887","title":"TNF-alpha gene polymorphism: clinical and biological implications.","date":"2000","source":"Microscopy research and technique","url":"https://pubmed.ncbi.nlm.nih.gov/10891887","citation_count":226,"is_preprint":false},{"pmid":"18929124","id":"PMC_18929124","title":"TNF-alpha signaling in glaucomatous neurodegeneration.","date":"2008","source":"Progress in brain research","url":"https://pubmed.ncbi.nlm.nih.gov/18929124","citation_count":221,"is_preprint":false},{"pmid":"11544310","id":"PMC_11544310","title":"Down-regulation of CD28 expression by TNF-alpha.","date":"2001","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/11544310","citation_count":216,"is_preprint":false},{"pmid":"12711593","id":"PMC_12711593","title":"TNF-alpha is a mitogen in skeletal muscle.","date":"2003","source":"American journal of physiology. Cell physiology","url":"https://pubmed.ncbi.nlm.nih.gov/12711593","citation_count":204,"is_preprint":false},{"pmid":"31921183","id":"PMC_31921183","title":"TNF-α Directly Enhances Osteocyte RANKL Expression and Promotes Osteoclast Formation.","date":"2019","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/31921183","citation_count":203,"is_preprint":false},{"pmid":"7759957","id":"PMC_7759957","title":"Matrix metalloproteinases and processing of pro-TNF-alpha.","date":"1995","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/7759957","citation_count":202,"is_preprint":false},{"pmid":"30170620","id":"PMC_30170620","title":"Unleashing endogenous TNF-alpha as a cancer immunotherapeutic.","date":"2018","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/30170620","citation_count":200,"is_preprint":false},{"pmid":"25887212","id":"PMC_25887212","title":"TNF-alpha inhibitors for ankylosing spondylitis.","date":"2015","source":"The Cochrane database of systematic reviews","url":"https://pubmed.ncbi.nlm.nih.gov/25887212","citation_count":199,"is_preprint":false},{"pmid":"21288189","id":"PMC_21288189","title":"Targeting TNF-α to elucidate and ameliorate neuroinflammation in neurodegenerative diseases.","date":"2011","source":"CNS & neurological disorders drug targets","url":"https://pubmed.ncbi.nlm.nih.gov/21288189","citation_count":195,"is_preprint":false},{"pmid":"16237274","id":"PMC_16237274","title":"TNF-alpha and pathologic bone resorption.","date":"2005","source":"The Keio journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/16237274","citation_count":179,"is_preprint":false},{"pmid":"19757404","id":"PMC_19757404","title":"TNF-alpha, a potent lipid metabolism regulator.","date":"2009","source":"Cell biochemistry and function","url":"https://pubmed.ncbi.nlm.nih.gov/19757404","citation_count":167,"is_preprint":false},{"pmid":"10719836","id":"PMC_10719836","title":"Tumor necrosis factor (TNF)-alpha and TNF receptors in viral pathogenesis.","date":"2000","source":"Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/10719836","citation_count":164,"is_preprint":false},{"pmid":"18504118","id":"PMC_18504118","title":"Depression, comorbidities and the TNF-alpha system.","date":"2008","source":"European psychiatry : the journal of the Association of European Psychiatrists","url":"https://pubmed.ncbi.nlm.nih.gov/18504118","citation_count":164,"is_preprint":false},{"pmid":"9917875","id":"PMC_9917875","title":"Sleep. A physiologic role for IL-1 beta and TNF-alpha.","date":"1998","source":"Annals of the New York Academy of Sciences","url":"https://pubmed.ncbi.nlm.nih.gov/9917875","citation_count":161,"is_preprint":false},{"pmid":"23628802","id":"PMC_23628802","title":"Regulation of TNF-α with a focus on rheumatoid arthritis.","date":"2013","source":"Immunology and cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/23628802","citation_count":157,"is_preprint":false},{"pmid":"1777835","id":"PMC_1777835","title":"TNF alpha mRNA expression in allergic inflammation.","date":"1991","source":"Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/1777835","citation_count":156,"is_preprint":false},{"pmid":"18655773","id":"PMC_18655773","title":"Regulation of PPARgamma function by TNF-alpha.","date":"2008","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/18655773","citation_count":149,"is_preprint":false},{"pmid":"11376190","id":"PMC_11376190","title":"TNF-alpha expression in painful and nonpainful neuropathies.","date":"2001","source":"Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/11376190","citation_count":138,"is_preprint":false},{"pmid":"1329840","id":"PMC_1329840","title":"Tumor necrosis factor (TNF-alpha) and lymphotoxin (TNF-beta).","date":"1992","source":"Current opinion in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/1329840","citation_count":134,"is_preprint":false},{"pmid":"33053859","id":"PMC_33053859","title":"Complexity of TNF-α Signaling in Heart Disease.","date":"2020","source":"Journal of clinical medicine","url":"https://pubmed.ncbi.nlm.nih.gov/33053859","citation_count":132,"is_preprint":false},{"pmid":"18316149","id":"PMC_18316149","title":"TNF-alpha as a molecular target in bipolar disorder.","date":"2008","source":"Progress in neuro-psychopharmacology & biological psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/18316149","citation_count":127,"is_preprint":false},{"pmid":"18825399","id":"PMC_18825399","title":"TNF-alpha production in the skin.","date":"2008","source":"Archives of dermatological research","url":"https://pubmed.ncbi.nlm.nih.gov/18825399","citation_count":125,"is_preprint":false},{"pmid":"25492727","id":"PMC_25492727","title":"Rapid mitochondrial dysfunction mediates TNF-alpha-induced neurotoxicity.","date":"2015","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25492727","citation_count":117,"is_preprint":false},{"pmid":"17447161","id":"PMC_17447161","title":"TNF-alpha alters visfatin and adiponectin levels in human fat.","date":"2007","source":"Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme","url":"https://pubmed.ncbi.nlm.nih.gov/17447161","citation_count":106,"is_preprint":false},{"pmid":"15625348","id":"PMC_15625348","title":"TNF-{alpha}, chronic hepatitis C and diabetes: a novel triad.","date":"2005","source":"QJM : monthly journal of the Association of Physicians","url":"https://pubmed.ncbi.nlm.nih.gov/15625348","citation_count":101,"is_preprint":false},{"pmid":"16846800","id":"PMC_16846800","title":"Modulating TNF-alpha signaling with natural products.","date":"2006","source":"Drug discovery today","url":"https://pubmed.ncbi.nlm.nih.gov/16846800","citation_count":98,"is_preprint":false},{"pmid":"20173391","id":"PMC_20173391","title":"TNF-alpha: an activator of CD4+FoxP3+TNFR2+ regulatory T cells.","date":"2010","source":"Current directions in autoimmunity","url":"https://pubmed.ncbi.nlm.nih.gov/20173391","citation_count":96,"is_preprint":false},{"pmid":"19506720","id":"PMC_19506720","title":"The TNF-alpha system: functional aspects in depression, narcolepsy and psychopharmacology.","date":"2008","source":"Current neuropharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/19506720","citation_count":95,"is_preprint":false},{"pmid":"19275693","id":"PMC_19275693","title":"TNF-alpha in tuberculosis: a cytokine with a split personality.","date":"2009","source":"Inflammation & allergy drug targets","url":"https://pubmed.ncbi.nlm.nih.gov/19275693","citation_count":94,"is_preprint":false},{"pmid":"27652081","id":"PMC_27652081","title":"TNF-α gene polymorphisms and expression.","date":"2016","source":"SpringerPlus","url":"https://pubmed.ncbi.nlm.nih.gov/27652081","citation_count":88,"is_preprint":false},{"pmid":"30591049","id":"PMC_30591049","title":"TNF-alpha and metalloproteases as key players in melanoma cells aggressiveness.","date":"2018","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/30591049","citation_count":83,"is_preprint":false},{"pmid":"1550865","id":"PMC_1550865","title":"Genomic structure, induction, and production of TNF-alpha.","date":"1992","source":"Immunology series","url":"https://pubmed.ncbi.nlm.nih.gov/1550865","citation_count":83,"is_preprint":false},{"pmid":"19277912","id":"PMC_19277912","title":"TNF-alpha and its inhibitors in cancer.","date":"2009","source":"Medical oncology (Northwood, London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/19277912","citation_count":82,"is_preprint":false},{"pmid":"37691196","id":"PMC_37691196","title":"At the Crossroads of TNF α Signaling and Cancer.","date":"2024","source":"Current molecular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/37691196","citation_count":81,"is_preprint":false},{"pmid":"29369823","id":"PMC_29369823","title":"iRhom2 promotes lupus nephritis through TNF-α and EGFR signaling.","date":"2018","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/29369823","citation_count":77,"is_preprint":false},{"pmid":"8933152","id":"PMC_8933152","title":"TNF-alpha-induced regulation and signalling in macrophages.","date":"1996","source":"Immunobiology","url":"https://pubmed.ncbi.nlm.nih.gov/8933152","citation_count":76,"is_preprint":false},{"pmid":"14617760","id":"PMC_14617760","title":"Antithrombotic activity of TNF-alpha.","date":"2003","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/14617760","citation_count":76,"is_preprint":false},{"pmid":"20625488","id":"PMC_20625488","title":"Anti-TNF-alpha therapies in systemic lupus erythematosus.","date":"2010","source":"Journal of biomedicine & biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/20625488","citation_count":74,"is_preprint":false},{"pmid":"10201952","id":"PMC_10201952","title":"TNF-alpha regulates corneal Langerhans cell migration.","date":"1999","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/10201952","citation_count":74,"is_preprint":false},{"pmid":"29559745","id":"PMC_29559745","title":"Transmembrane TNF-alpha promotes chemoresistance in breast cancer cells.","date":"2018","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/29559745","citation_count":68,"is_preprint":false},{"pmid":"21384095","id":"PMC_21384095","title":"Implications of TNF-α in the pathogenesis and management of GVHD.","date":"2011","source":"International journal of hematology","url":"https://pubmed.ncbi.nlm.nih.gov/21384095","citation_count":65,"is_preprint":false},{"pmid":"11953838","id":"PMC_11953838","title":"TNF-alpha is involved in activating DNA fragmentation in skeletal muscle.","date":"2002","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/11953838","citation_count":65,"is_preprint":false},{"pmid":"26419478","id":"PMC_26419478","title":"TNF-α: a treatment target or cause of sarcoidosis?","date":"2015","source":"Journal of the European Academy of Dermatology and Venereology : JEADV","url":"https://pubmed.ncbi.nlm.nih.gov/26419478","citation_count":64,"is_preprint":false},{"pmid":"28127258","id":"PMC_28127258","title":"TNF-α sensitizes chemotherapy and radiotherapy against breast cancer cells.","date":"2017","source":"Cancer cell international","url":"https://pubmed.ncbi.nlm.nih.gov/28127258","citation_count":63,"is_preprint":false},{"pmid":"17017952","id":"PMC_17017952","title":"Anti-TNF-alpha antibody therapies in autoimmune diseases.","date":"2006","source":"Current topics in medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17017952","citation_count":62,"is_preprint":false},{"pmid":"30826358","id":"PMC_30826358","title":"Cortistatin binds to TNF-α receptors and protects against osteoarthritis.","date":"2019","source":"EBioMedicine","url":"https://pubmed.ncbi.nlm.nih.gov/30826358","citation_count":60,"is_preprint":false},{"pmid":"21559854","id":"PMC_21559854","title":"Role of TNF-alpha during central sensitization in preclinical studies.","date":"2011","source":"Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology","url":"https://pubmed.ncbi.nlm.nih.gov/21559854","citation_count":60,"is_preprint":false},{"pmid":"27831558","id":"PMC_27831558","title":"RIPK1 protects from TNF-α-mediated liver damage during hepatitis.","date":"2016","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/27831558","citation_count":59,"is_preprint":false},{"pmid":"26407855","id":"PMC_26407855","title":"The multimerization and secretion of adiponectin are regulated by TNF-alpha.","date":"2015","source":"Endocrine","url":"https://pubmed.ncbi.nlm.nih.gov/26407855","citation_count":58,"is_preprint":false},{"pmid":"27358858","id":"PMC_27358858","title":"TNF-α, a good or bad factor in hematological diseases?","date":"2014","source":"Stem cell investigation","url":"https://pubmed.ncbi.nlm.nih.gov/27358858","citation_count":54,"is_preprint":false},{"pmid":"29336470","id":"PMC_29336470","title":"TNF-α induces Drp1-mediated mitochondrial fragmentation during inflammatory cardiomyocyte injury.","date":"2018","source":"International journal of molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/29336470","citation_count":54,"is_preprint":false},{"pmid":"18693138","id":"PMC_18693138","title":"Interpreting crosstalk between TNF-alpha and NGF: potential implications for disease.","date":"2008","source":"Trends in molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/18693138","citation_count":53,"is_preprint":false},{"pmid":"11889578","id":"PMC_11889578","title":"Stimulation of TNF alpha expression by hyperosmotic stress.","date":"2002","source":"Pflugers Archiv : European journal of physiology","url":"https://pubmed.ncbi.nlm.nih.gov/11889578","citation_count":51,"is_preprint":false},{"pmid":"20870895","id":"PMC_20870895","title":"Molecular pathways of spontaneous and TNF-{alpha}-mediated neutrophil apoptosis under intermittent hypoxia.","date":"2010","source":"American journal of respiratory cell and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/20870895","citation_count":47,"is_preprint":false},{"pmid":"32069267","id":"PMC_32069267","title":"TNF-α regulates diabetic macrophage function through the histone acetyltransferase MOF.","date":"2020","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/32069267","citation_count":46,"is_preprint":false},{"pmid":"23890415","id":"PMC_23890415","title":"TNF-α signaling in Fanconi anemia.","date":"2013","source":"Blood cells, molecules & diseases","url":"https://pubmed.ncbi.nlm.nih.gov/23890415","citation_count":45,"is_preprint":false},{"pmid":"19136378","id":"PMC_19136378","title":"Infliximab and the TNF-alpha system.","date":"2009","source":"American journal of physiology. Gastrointestinal and liver physiology","url":"https://pubmed.ncbi.nlm.nih.gov/19136378","citation_count":45,"is_preprint":false},{"pmid":"7535144","id":"PMC_7535144","title":"TNF-alpha, the great imitator: role of p55 and p75 TNF receptors in hematopoiesis.","date":"1994","source":"Stem cells (Dayton, Ohio)","url":"https://pubmed.ncbi.nlm.nih.gov/7535144","citation_count":44,"is_preprint":false},{"pmid":"26088424","id":"PMC_26088424","title":"Effects of TNF-α on Cementoblast Differentiation, Mineralization, and Apoptosis.","date":"2015","source":"Journal of dental research","url":"https://pubmed.ncbi.nlm.nih.gov/26088424","citation_count":44,"is_preprint":false},{"pmid":"25306394","id":"PMC_25306394","title":"TNF-α promotes invasive growth through the MET signaling pathway.","date":"2014","source":"Molecular oncology","url":"https://pubmed.ncbi.nlm.nih.gov/25306394","citation_count":44,"is_preprint":false},{"pmid":"11506387","id":"PMC_11506387","title":"Targets of glucocorticoid action on TNF-alpha release by macrophages.","date":"2001","source":"Inflammation research : official journal of the European Histamine Research Society ... [et al.]","url":"https://pubmed.ncbi.nlm.nih.gov/11506387","citation_count":44,"is_preprint":false},{"pmid":"11817710","id":"PMC_11817710","title":"Leptin, insulin and TNF-alpha in weight loss.","date":"2001","source":"Journal of endocrinological investigation","url":"https://pubmed.ncbi.nlm.nih.gov/11817710","citation_count":44,"is_preprint":false},{"pmid":"9737713","id":"PMC_9737713","title":"BRE: a modulator of TNF-alpha action.","date":"1998","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/9737713","citation_count":44,"is_preprint":false},{"pmid":"14593215","id":"PMC_14593215","title":"TNF-alpha and TNF-beta gene polymorphisms in cerebral infarction.","date":"2003","source":"Journal of molecular neuroscience : MN","url":"https://pubmed.ncbi.nlm.nih.gov/14593215","citation_count":44,"is_preprint":false},{"pmid":"17298451","id":"PMC_17298451","title":"NRAMP1 and TNF-alpha polymorphisms and susceptibility to tuberculosis in Thais.","date":"2007","source":"Respirology (Carlton, Vic.)","url":"https://pubmed.ncbi.nlm.nih.gov/17298451","citation_count":44,"is_preprint":false},{"pmid":"35687009","id":"PMC_35687009","title":"TNF-α/anti-TNF-α drugs and its effect on pregnancy outcomes.","date":"2022","source":"Expert reviews in molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/35687009","citation_count":43,"is_preprint":false},{"pmid":"19324019","id":"PMC_19324019","title":"IGFBP-3, hypoxia and TNF-alpha inhibit adiponectin transcription.","date":"2009","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/19324019","citation_count":43,"is_preprint":false},{"pmid":"17902045","id":"PMC_17902045","title":"Induction of TNF-alpha by LPS in Schwann cell is regulated by MAPK activation signals.","date":"2007","source":"Cellular and molecular neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/17902045","citation_count":43,"is_preprint":false},{"pmid":"12110119","id":"PMC_12110119","title":"Perspectives for TNF-alpha-targeting therapies.","date":"2002","source":"Arthritis research","url":"https://pubmed.ncbi.nlm.nih.gov/12110119","citation_count":42,"is_preprint":false},{"pmid":"11696370","id":"PMC_11696370","title":"TNF-alpha enhances intracellular glucocorticoid availability.","date":"2001","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/11696370","citation_count":42,"is_preprint":false},{"pmid":"22650377","id":"PMC_22650377","title":"TNF α signaling beholds thalidomide saga: a review of mechanistic role of TNF-α signaling under thalidomide.","date":"2012","source":"Current topics in medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/22650377","citation_count":42,"is_preprint":false},{"pmid":"30958728","id":"PMC_30958728","title":"Targeted TNF-α Overexpression Drives Salivary Gland Inflammation.","date":"2019","source":"Journal of dental research","url":"https://pubmed.ncbi.nlm.nih.gov/30958728","citation_count":42,"is_preprint":false},{"pmid":"22487520","id":"PMC_22487520","title":"TNF-alpha gene (TNFA) variants increase risk for multi-organ dysfunction syndrome (MODS) in acute pancreatitis.","date":"2012","source":"Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]","url":"https://pubmed.ncbi.nlm.nih.gov/22487520","citation_count":41,"is_preprint":false},{"pmid":"17591895","id":"PMC_17591895","title":"The role of soluble TNF receptors for TNF-alpha in uveitis.","date":"2007","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/17591895","citation_count":41,"is_preprint":false},{"pmid":"28692806","id":"PMC_28692806","title":"MicroRNA-155-3p Mediates TNF-α-Inhibited Cementoblast Differentiation.","date":"2017","source":"Journal of dental research","url":"https://pubmed.ncbi.nlm.nih.gov/28692806","citation_count":38,"is_preprint":false},{"pmid":"33135824","id":"PMC_33135824","title":"TNF-α signaling regulates RUNX1 function in endothelial cells.","date":"2020","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/33135824","citation_count":38,"is_preprint":false},{"pmid":"15853670","id":"PMC_15853670","title":"TNF(alpha) modulation of visceral and spinal sensory processing.","date":"2005","source":"Current pharmaceutical design","url":"https://pubmed.ncbi.nlm.nih.gov/15853670","citation_count":38,"is_preprint":false},{"pmid":"19267854","id":"PMC_19267854","title":"TNF-alpha infusion impairs corpora cavernosa reactivity.","date":"2009","source":"The journal of sexual medicine","url":"https://pubmed.ncbi.nlm.nih.gov/19267854","citation_count":37,"is_preprint":false},{"pmid":"18557926","id":"PMC_18557926","title":"TNF-alpha stimulates Akt by a distinct aPKC-dependent pathway in premalignant keratinocytes.","date":"2008","source":"Experimental dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/18557926","citation_count":36,"is_preprint":false},{"pmid":"25603656","id":"PMC_25603656","title":"TNF-alpha: a risk factor for ischemic stroke.","date":"2014","source":"Journal of Ayub Medical College, Abbottabad : JAMC","url":"https://pubmed.ncbi.nlm.nih.gov/25603656","citation_count":36,"is_preprint":false},{"pmid":"21853060","id":"PMC_21853060","title":"Differential effects of TNF (TNFSF2) and IFN-γ on intestinal epithelial cell morphogenesis and barrier function in three-dimensional culture.","date":"2011","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/21853060","citation_count":34,"is_preprint":false},{"pmid":"32344470","id":"PMC_32344470","title":"TNF-α-induced p53 activation induces apoptosis in neurological injury.","date":"2020","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/32344470","citation_count":34,"is_preprint":false},{"pmid":"25391899","id":"PMC_25391899","title":"TNF-α-mediated cardiorenal injury after rhabdomyolysis in rats.","date":"2014","source":"American journal of physiology. Renal physiology","url":"https://pubmed.ncbi.nlm.nih.gov/25391899","citation_count":34,"is_preprint":false},{"pmid":"27062372","id":"PMC_27062372","title":"TNF-α downregulates CIDEC via MEK/ERK pathway in human adipocytes.","date":"2016","source":"Obesity (Silver Spring, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/27062372","citation_count":33,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":47169,"output_tokens":7446,"usd":0.126599,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":16894,"output_tokens":4548,"usd":0.099085,"stage2_stop_reason":"end_turn"},"total_usd":0.225684,"stage1_batch_id":"msgbatch_017qqVz33Ga63SCDwzb35XPb","stage2_batch_id":"msgbatch_01Scr2Ei9x4HJMiRGxwrmvLK","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2008,\n      \"finding\": \"TNF-alpha induces two distinct caspase-8 activation pathways: (1) cycloheximide co-treatment promotes caspase-8 activation by eliminating c-FLIP, independent of RIPK1; (2) Smac mimetic triggers autodegradation of cIAP1/2, releasing RIPK1 from the TNF receptor complex to form a caspase-8-activating complex consisting of RIPK1, FADD, and caspase-8, a process requiring CYLD (a RIPK1 K63 deubiquitinating enzyme).\",\n      \"method\": \"Cell-based signaling assays, pharmacological inhibition (cycloheximide, Smac mimetic), genetic manipulation of cIAP1/2, RIPK1, CYLD, and c-FLIP\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal genetic and pharmacological approaches in a single rigorous study, pathway placement confirmed\",\n      \"pmids\": [\"18485876\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"TNF-alpha acts as a homotrimer that binds to either TNFR1 (55 kDa) or TNFR2 (75 kDa); crystal structures of TNF-alpha, TNF-beta, ectodomain of TNFR1, and the TNF-beta/sTNFR-1 complex have been determined, defining structure-function relationships including cysteine-rich extracellular repeat domains on receptors.\",\n      \"method\": \"X-ray crystallography, structural biology\",\n      \"journal\": \"Microscopy research and technique\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structures solved and replicated across multiple studies cited in review\",\n      \"pmids\": [\"10891884\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Transmembrane TNF-alpha (tmTNF-alpha) acts as a bipolar molecule: it transmits forward signals as a ligand by binding TNFR1/TNFR2 on target cells, and also acts as a receptor transmitting reverse (outside-to-inside) signals back to the producing cell upon binding of its native receptors.\",\n      \"method\": \"Cell-based signaling assays with transmembrane vs. soluble TNF-alpha constructs; functional differentiation from soluble form via receptor binding studies\",\n      \"journal\": \"Rheumatology (Oxford, England)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — review summarizing accumulated experimental evidence from multiple studies, but no single primary experiment described in abstract\",\n      \"pmids\": [\"20194223\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Transmembrane TNF-alpha is cleaved from the cell surface by TNF-alpha-converting enzyme (TACE/ADAM17) to generate the soluble form of TNF-alpha.\",\n      \"method\": \"Biochemical cleavage assays; metalloprotease inhibition studies\",\n      \"journal\": \"Rheumatology (Oxford, England)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — established mechanism summarized in review, supported by multiple prior experimental studies\",\n      \"pmids\": [\"20194223\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"Matrix metalloproteinases (MMPs) — including stromelysin, matrilysin, collagenase, and gelatinases — can cleave a recombinant pro-TNF substrate to yield mature TNF-alpha in vitro; broad-spectrum MMP inhibitors prevent processing of the TNF precursor and reduce blood TNF levels after endotoxin administration in rats.\",\n      \"method\": \"In vitro cleavage assay with purified MMPs and recombinant pro-TNF substrate; MMP inhibitors in vivo (rat endotoxin model)\",\n      \"journal\": \"Journal of leukocyte biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstitution with purified enzymes plus in vivo pharmacological validation\",\n      \"pmids\": [\"7759957\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"A small-molecule inhibitor of TNF-alpha promotes subunit disassembly of the trimeric cytokine by forming an intermediate complex with the intact trimer, accelerating subunit dissociation 600-fold and leading to a compound-dimer complex. X-ray crystallography revealed a single compound molecule displaces one subunit from the trimer.\",\n      \"method\": \"X-ray crystallography, biochemical dissociation kinetics assay, cell-based inhibition assay\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structure plus in vitro reconstitution and kinetics, multiple orthogonal methods in one study\",\n      \"pmids\": [\"16284179\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"TNF-alpha promotes oligodendrocyte progenitor proliferation and remyelination through TNFR2 (not TNFR1); mice lacking TNFR2 showed delayed remyelination and reduced pools of proliferating NG2+ oligodendrocyte progenitors and mature oligodendrocytes after cuprizone-induced demyelination.\",\n      \"method\": \"Genetic knockout mice (TNF-alpha-/-, TNFR1-/-, TNFR2-/-), histology, immunohistochemistry, electron microscopy, BrdU labeling\",\n      \"journal\": \"Nature neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple receptor-specific knockout lines with morphometric and proliferation readouts\",\n      \"pmids\": [\"11600888\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"TNF-alpha mediates insulin resistance through serine phosphorylation of IRS-1, impairing insulin receptor tyrosine phosphorylation signaling; TNF-alpha knockout obese mice showed approximately 2-fold increased insulin-stimulated tyrosine phosphorylation of the insulin receptor in muscle and adipose tissue compared to wild-type obese mice.\",\n      \"method\": \"TNF-alpha and TNF receptor knockout mice (ob/ob background, diet-induced obesity), glucose/insulin tolerance tests, phosphorylation assays\",\n      \"journal\": \"Experimental and clinical endocrinology & diabetes\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple receptor-specific knockout lines with biochemical phosphorylation readouts and metabolic phenotyping\",\n      \"pmids\": [\"10320052\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"BRE protein was identified as a binding partner for the cytoplasmic/juxtamembrane domain of the p55 TNF receptor (TNFR1) via yeast two-hybrid screen and confirmed by in vitro biochemical pulldown with recombinant fusion proteins and co-immunoprecipitation in transfected mammalian cells; BRE specifically interacted with p55 TNFR but not p75 TNFR, Fas, or p75 neurotrophin receptor. Overexpression of BRE inhibited TNF-induced NF-κB activation.\",\n      \"method\": \"Yeast two-hybrid screen, in vitro pulldown with recombinant fusion proteins, co-immunoprecipitation, NF-κB reporter assay\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP plus in vitro pulldown plus functional NF-κB reporter, multiple orthogonal methods\",\n      \"pmids\": [\"9737713\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"TNF-alpha activates the MAPK cascade in macrophages via sequential activation of MEKK and MEK1 in a c-Raf-1- and Raf-B-independent fashion downstream of CD120a (p55 TNFR); MEKK activity peaked within 30 seconds of TNF-alpha exposure, temporally preceding peak activation of p42mapk/ERK2.\",\n      \"method\": \"Kinase activity assays, temporal signaling analysis in mouse macrophages, pharmacological dissection\",\n      \"journal\": \"Immunobiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — kinase cascade assays in macrophages, single lab, single study\",\n      \"pmids\": [\"8933152\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"In vivo TNF-alpha at sepsis-level doses transiently inhibits thrombus formation via iNOS-dependent generation of NO in the vessel wall; this antithrombotic effect requires iNOS (abolished in iNOS-deficient mice) and is not exerted directly on platelets. TNF receptor 1- and 2-deficient mice showed normal thrombogenesis in the presence of TNF-alpha.\",\n      \"method\": \"Intravital microscopy, iNOS-knockout and TNFR1/TNFR2-deficient mice, platelet function assays, bleeding time measurement\",\n      \"journal\": \"Journal of Clinical Investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple genetic knockout lines plus intravital imaging, mechanistic pathway confirmed by receptor and enzyme deficiency\",\n      \"pmids\": [\"14617760\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"TNF-alpha mediates corneal Langerhans cell migration through both TNFR1 (p55) and TNFR2 (p75) signaling; IL-1-induced LC migration is largely mediated by TNFR function, while TNF-alpha-induced LC migration is independent of IL-1 receptor I activity.\",\n      \"method\": \"Gene-targeted knockout mice (IL-1RI-/-, p55-/-, p75-/-, double p55/p75-/-), immunofluorescence migration assay, cytokine injection\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple receptor-specific knockout lines with quantitative migration assay and epistasis analysis\",\n      \"pmids\": [\"10201952\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"iRhom2 regulates ADAM17-dependent shedding of TNF-alpha and HB-EGF; deficiency of iRhom2 simultaneously blocks TNF-alpha and EGFR (HB-EGF) signaling in the kidney, protecting against lupus nephritis without altering anti-dsDNA antibody production.\",\n      \"method\": \"iRhom2-knockout in Fcgr2b-/- lupus-prone mice, transcriptome profiling, pharmacological blockade of TNF-alpha and EGFR\",\n      \"journal\": \"Journal of Clinical Investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic knockout with unbiased transcriptome profiling and orthogonal pharmacological validation\",\n      \"pmids\": [\"29369823\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Transmembrane TNF-alpha (tmTNF-alpha) mediates doxorubicin resistance in breast cancer cells through reverse signaling via the tmTNF-alpha/NTF-ERK-GST-π axis and tmTNF-alpha/NTF-NF-κB-mediated anti-apoptotic pathways; the intracellular domain of tmTNF-alpha is required, as overexpression of the N-terminal fragment (NTF) containing the intracellular domain was sufficient to induce resistance.\",\n      \"method\": \"tmTNF-alpha overexpression/knockdown, NTF mutant constructs, Western blot, xenograft mouse model\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — domain-specific mutants plus in vivo xenograft, single lab\",\n      \"pmids\": [\"29559745\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"TNF-alpha directly induces RANKL mRNA expression in osteocytes through activation of MAPKs and NF-κB (p65 nuclear translocation), leading to enhanced osteoclastogenesis; MAPK inhibitors significantly decreased TNF-alpha-induced RANKL expression in osteocytes.\",\n      \"method\": \"Primary osteocyte isolation by FACS from Dmp1-Topaz mice, co-culture with TNFR-deficient osteoclast precursors, Western blot for MAPK phosphorylation, in vivo calvarial injection, TRAP staining\",\n      \"journal\": \"Frontiers in immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — primary cell isolation, receptor-deficient co-culture system, in vitro and in vivo validation with inhibitor confirmation\",\n      \"pmids\": [\"31921183\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"RIPK1 serves as a scaffold protecting hepatocytes from TNF-alpha-triggered apoptosis; in mice lacking RIPK1 specifically in liver parenchymal cells (Ripk1LPC-KO), ConA-induced hepatitis leads to TNF-alpha-driven massive apoptotic cell death. RIPK1 kinase activity contributes to caspase-independent necrotic cell death.\",\n      \"method\": \"Conditional knockout mice (Ripk1LPC-KO) and RIPK1 kinase-dead knock-in mice (Ripk1K45A), concanavalin A hepatitis model, caspase activity assays\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — two complementary genetic mouse models separating scaffold vs. kinase function, defined cellular phenotype\",\n      \"pmids\": [\"27831558\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"TNF-alpha directly inhibits CD28 gene transcription in T cells by inactivating DNA-protein complex formation at two sequence motifs corresponding to the transcriptional initiator of the CD28 gene; nuclear extracts from TNF-alpha-treated cells failed to activate transcription from templates under control of the CD28 initiator sequences in in vitro transcription assays.\",\n      \"method\": \"Reporter gene assays, electrophoretic mobility shift assay (EMSA), in vitro transcription assay, T cell line/clone culture\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro transcription reconstitution plus EMSA plus reporter assay, multiple orthogonal methods\",\n      \"pmids\": [\"11544310\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"TNF-alpha induces mitochondrial dysfunction in neurons through TNFR1 (not TNFR2), involving caspase-8 activation, decrease in mitochondrial membrane potential, and cytochrome c release from mitochondria into the cytosol; pre-treatment with TNFR1 antibody ameliorated neurotoxic effects.\",\n      \"method\": \"Mitochondrial function assays (basal respiration, ATP production), receptor-specific antibody blockade, caspase-8 activity assay, mitochondrial membrane potential measurement, cytochrome c subcellular fractionation\",\n      \"journal\": \"Journal of neurochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — receptor-specific blockade with multiple functional readouts, single lab\",\n      \"pmids\": [\"25492727\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"TNF-alpha acts as a mitogen in skeletal muscle by activating satellite cells to enter the cell cycle (G1-to-S phase transition) through stimulation of serum response factor (SRF) binding to the serum response element (SRE) in the c-fos gene promoter and activation of early response gene expression.\",\n      \"method\": \"BrdU incorporation assay in primary myoblasts and adult mouse muscle (in vivo injection), SRF-SRE binding assay, reporter gene assay\",\n      \"journal\": \"American journal of physiology. Cell physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro and in vivo BrdU assays plus SRF binding mechanism, single lab\",\n      \"pmids\": [\"12711593\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"TNF-alpha suppresses multimerization and secretion of adiponectin by downregulating ER-resident chaperones ERO1-La, DsbA-L, and ERp44, impairing disulfide bond modification; TNF-alpha treatment enhanced the interaction between adiponectin and ERp44. PPARγ overexpression antagonized these effects by directly binding PPRE elements of ERO1-La and DsbA-L promoters.\",\n      \"method\": \"In vitro and in vivo adiponectin multimerization assays, Co-IP (adiponectin-ERp44 interaction), Western blot, ChIP assay for PPARγ binding\",\n      \"journal\": \"Endocrine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP plus ChIP plus functional rescue, single lab\",\n      \"pmids\": [\"26407855\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"TNF-alpha promotes invasive growth by inducing MET receptor tyrosine kinase transcription via NF-κB; MET then sustains MEK/ERK activation and Snail accumulation leading to E-cadherin downregulation. TNF-alpha also induces HGF secretion by fibroblasts, creating a paracrine HGF/MET pro-invasive loop.\",\n      \"method\": \"MET-specific inhibitors (small molecules, antibodies, siRNA), NF-κB pathway analysis, Western blot for Snail and E-cadherin, invasion assays\",\n      \"journal\": \"Molecular oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple MET inhibition approaches plus mechanistic pathway dissection, single lab\",\n      \"pmids\": [\"25306394\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"TNF-alpha inhibits 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2) activity and mRNA expression in LLC-PK1 cells via MEK/ERK and p38 MAPK pathways (not PKC), thereby enhancing glucocorticoid access to receptors; the effect was reversed by ERK inhibitor PD-098050, p38 inhibitor SB-202190, or PKA activator forskolin. Overexpression of MEK1 down-regulated 11β-HSD2 activity.\",\n      \"method\": \"Enzyme activity assays, mRNA quantification, kinase inhibitors, MEK1 overexpression, PKC inhibitor GF-109203X\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological dissection plus MEK1 overexpression, multiple inhibitors tested, single lab\",\n      \"pmids\": [\"11696370\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"TNF-alpha induces Drp1-mediated mitochondrial fragmentation in cardiomyocytes through activation of RhoA and the RhoA/ROCK pathway, which phosphorylates Drp1 at Ser616 and promotes its mitochondrial translocation; ROCK inhibitors (Y-27632 and fasudil) attenuated TNF-alpha-induced p-Drp1 Ser616, mitochondrial Drp1 accumulation, and mitochondrial fragmentation.\",\n      \"method\": \"Western blot for Drp1 and p-Drp1 Ser616, confocal microscopy for mitochondrial morphology, ROCK inhibitors, in vitro H9C2 cardiomyocytes\",\n      \"journal\": \"International journal of molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological pathway dissection with morphological and biochemical readouts, single lab\",\n      \"pmids\": [\"29336470\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"TNF-alpha downregulates CIDEC expression in human adipocytes through the MEK/ERK pathway by phosphorylating PPARγ and causing its nuclear export; constitutively active MEK1 mutant recapitulated TNF-alpha effects, and MEK/ERK inhibition prevented TNF-alpha-mediated CIDEC downregulation. Reporter assay confirmed direct reduction in CIDEC transcription.\",\n      \"method\": \"Selective kinase inhibitors, RNAi, constitutively active MEK1 mutant, immunofluorescence, subcellular fractionation, luciferase reporter assay\",\n      \"journal\": \"Obesity (Silver Spring)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple genetic/pharmacological perturbations plus reporter assay, single lab\",\n      \"pmids\": [\"27062372\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"TNF-alpha activates Akt and ERK1/2 in premalignant keratinocytes through an atypical protein kinase C (aPKC, zeta/iota-lambda)-, NF-κB-, and hydroxyl radical-dependent pathway; aPKC peptide inhibitor abrogated TNF-alpha effects on Akt and ERK1/2 but increased p38 activation. Iron chelation (blocking OH radical formation) abolished Akt/ERK signaling.\",\n      \"method\": \"Specific peptide inhibitors for aPKC, NF-κB inhibitors, p38 inhibitors, iron chelator desferroxamine, phosphorylation assays in HaCaT cells\",\n      \"journal\": \"Experimental dermatology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple pathway inhibitors with defined signaling bifurcation, single lab\",\n      \"pmids\": [\"18557926\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Cortistatin (CST) competitively binds to both TNFR1 and TNFR2, suppressing TNF-alpha proinflammatory signaling; CST inhibits NF-κB pathway activation in osteoarthritis, and TNFR1/TNFR2 knockout mice implicated these receptors as required for CST's protective role.\",\n      \"method\": \"Co-immunoprecipitation, biotin-based solid-phase binding assay, Western blot, TNFR1/TNFR2-knockout mice, OA models\",\n      \"journal\": \"EBioMedicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal binding assays plus receptor-deficient mice, single lab\",\n      \"pmids\": [\"30826358\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"TNF-alpha mediates skeletal muscle DNA fragmentation (apoptosis) during cancer cachexia; mice deficient in TNFR1 (p55) showed a markedly attenuated increase in muscle DNA fragmentation (2.1-fold vs. 9.8-fold in wild-type) upon Lewis lung carcinoma inoculation.\",\n      \"method\": \"TNF-alpha administration to rats, TNFR1 gene-deficient mice with Lewis lung carcinoma, DNA fragmentation (laddering) assay\",\n      \"journal\": \"British journal of cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — receptor-deficient mice with quantitative DNA fragmentation assay, single lab\",\n      \"pmids\": [\"11953838\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"TNF-alpha stimulates expression of the histone acetyltransferase MOF in macrophages, and MOF acts as a coactivator of NF-κB-mediated inflammatory gene transcription; ChIP showed elevated H4K16 acetylation on inflammatory gene promoters in diabetic wound macrophages; etanercept (TNF-α inhibitor) treatment reduced MOF levels and improved diabetic wound healing.\",\n      \"method\": \"Myeloid-specific Mof-knockout mice (Lyz2Cre Moffl/fl), ChIP for H4K16ac, diet-induced obesity model, etanercept treatment\",\n      \"journal\": \"JCI insight\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — conditional knockout with ChIP and pharmacological validation, single lab\",\n      \"pmids\": [\"32069267\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"TNF-alpha (TNFSF2) increases intestinal epithelial paracellular permeability via caspase-driven apoptosis and cell shedding (distinct from IFNγ mechanism which does not involve apoptosis); TNF-alpha also fundamentally alters intestinal epithelial morphogenesis through its pro-apoptotic effect. Infliximab and adalimumab blocked these effects.\",\n      \"method\": \"Three-dimensional intestinal epithelial cell culture system, permeability assays, caspase inhibition, anti-TNF antibody treatment, tight junction protein localization\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — 3D culture model with pharmacological rescue and comparative cytokine dissection, single lab\",\n      \"pmids\": [\"21853060\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"TNF-alpha induces RUNX1 expression in retinal endothelial cells via JNK activation (not NF-κB or p38/MAPK), linking through Activator Protein 1 (AP-1) in a JNK-AP-1-RUNX1 regulatory feedback loop; JNK inhibitors also blocked high D-glucose-stimulated RUNX1 expression.\",\n      \"method\": \"TNF-α pathway inhibitors in HRMECs, Western blot, JNK/NF-κB/p38 inhibitors\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — pathway inhibitor dissection, single lab, single study\",\n      \"pmids\": [\"33135824\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"TNF-alpha is a homotrimeric cytokine that signals through two receptors (TNFR1/p55 and TNFR2/p75); it is proteolytically shed from the membrane-anchored precursor by TACE/ADAM17 and matrix metalloproteinases, while the transmembrane form mediates bidirectional signaling. Upon receptor engagement, TNF-alpha activates NF-κB and MAPK cascades, and depending on cellular context and co-stimuli induces two mechanistically distinct caspase-8 activation pathways leading to apoptosis or necroptosis (via a RIPK1–FADD–caspase-8 complex regulated by cIAP1/2, CYLD, and c-FLIP), triggers mitochondrial dysfunction through TNFR1, drives osteoclastogenesis via osteocyte RANKL induction through MAPK/NF-κB, mediates insulin resistance through serine phosphorylation of IRS-1, promotes satellite cell proliferation in muscle via SRF/SRE activation, supports oligodendrocyte progenitor renewal through TNFR2, and exerts antithrombotic effects via iNOS-dependent NO generation in the vessel wall.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"TNF-alpha is a homotrimeric cytokine that acts as a master regulator of inflammation, cell death, and tissue remodeling by engaging two distinct receptors, TNFR1 (p55) and TNFR2 (p75), each bearing cysteine-rich extracellular repeats that recognize the trimeric ligand [#1]. It is synthesized as a transmembrane precursor that is proteolytically shed to release the soluble cytokine by the TACE/ADAM17 sheddase — itself dependent on iRhom2 — and, independently, by matrix metalloproteinases that process pro-TNF both in vitro and in vivo [#3, #12, #4]. The transmembrane form is bidirectional, transmitting forward signals as a ligand and reverse (outside-to-inside) signals back into the producing cell [#2]. A defining feature of TNF-alpha signaling is its control over caspase-8-dependent death: it engages two mechanistically distinct routes, one driven by loss of c-FLIP and independent of RIPK1, and a second in which cIAP1/2 autodegradation releases RIPK1 to assemble a CYLD-dependent RIPK1–FADD–caspase-8 death complex [#0], with RIPK1 acting as a scaffold that protects cells from TNF-driven apoptosis while its kinase activity drives necrotic death [#15]. Through TNFR1, TNF-alpha precipitates mitochondrial dysfunction and apoptotic tissue loss [#17, #26], whereas TNFR2 mediates regenerative outputs such as oligodendrocyte progenitor proliferation and remyelination [#6]. TNF-alpha couples receptor engagement to NF-κB and MAPK cascades [#9, #8], driving osteocyte RANKL induction and osteoclastogenesis [#14], metabolic disruption including IRS-1-mediated insulin resistance and suppression of adiponectin assembly [#7, #19], and pro-invasive and inflammatory transcriptional programs [#20, #27]. Receptor-blocking and pathway-modulating agents — including the trimer-disassembling small molecule, anti-TNF antibodies, and competitive ligands such as cortistatin — define multiple points at which this signaling can be intercepted [#5, #28, #25].\",\n  \"teleology\": [\n    {\n      \"year\": 1995,\n      \"claim\": \"Established that mature soluble TNF-alpha can be liberated from its precursor by proteolytic processing, identifying matrix metalloproteinases as candidate sheddases controlling circulating TNF levels.\",\n      \"evidence\": \"In vitro cleavage of recombinant pro-TNF by purified MMPs and MMP-inhibitor blockade of TNF release in a rat endotoxin model\",\n      \"pmids\": [\"7759957\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not establish the dominant physiological sheddase versus ADAM17\", \"No structural definition of the cleavage site\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Defined how TNFR1 engagement is transduced into MAPK signaling, placing MEKK and MEK1 upstream of ERK independent of c-Raf-1/Raf-B.\",\n      \"evidence\": \"Temporal kinase activity assays and pharmacological dissection in mouse macrophages\",\n      \"pmids\": [\"8933152\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab, single cell type\", \"Direct receptor-to-MEKK linkage not biochemically reconstituted\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Identified a receptor-proximal regulator by showing BRE binds the TNFR1 cytoplasmic domain and dampens TNF-induced NF-κB activation, providing receptor specificity at the signaling interface.\",\n      \"evidence\": \"Yeast two-hybrid, reciprocal Co-IP and in vitro pulldown, NF-κB reporter assay\",\n      \"pmids\": [\"9737713\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which BRE inhibits NF-κB not resolved\", \"Physiological relevance in primary cells untested\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Demonstrated receptor-specific physiological roles, linking TNFR1 to IRS-1 serine phosphorylation and insulin resistance, and both receptors to Langerhans cell migration.\",\n      \"evidence\": \"TNF-alpha and receptor knockout mice with phosphorylation/metabolic phenotyping and quantitative migration assays\",\n      \"pmids\": [\"10320052\", \"10201952\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Kinase responsible for IRS-1 serine phosphorylation not identified\", \"Receptor-specific contributions to migration not fully separated\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Provided the structural basis for TNF-alpha action by defining the homotrimeric ligand and its receptor-binding architecture.\",\n      \"evidence\": \"X-ray crystal structures of TNF-alpha, TNF-beta, TNFR1 ectodomain, and a TNF-beta/sTNFR-1 complex\",\n      \"pmids\": [\"10891884\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No structure of full TNF-alpha/TNFR1 or TNFR2 signaling complexes described\", \"Transmembrane form not structurally resolved\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Extended TNF-alpha into transcriptional and enzymatic control, showing it represses CD28 transcription in T cells and inhibits 11β-HSD2 via MAPK pathways.\",\n      \"evidence\": \"EMSA, in vitro transcription and reporter assays in T cells; enzyme activity assays with MEK/ERK and p38 inhibitors in LLC-PK1 cells\",\n      \"pmids\": [\"11544310\", \"11696370\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Transcription factors mediating CD28 repression not identified\", \"Cell-type generality of 11β-HSD2 effect untested\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Revealed context-dependent and even regenerative/protective outputs: TNF-alpha acts as a satellite-cell mitogen via SRF/SRE and exerts a transient iNOS-dependent antithrombotic effect in the vessel wall.\",\n      \"evidence\": \"BrdU and SRF-SRE binding assays in myoblasts; intravital microscopy in iNOS- and TNFR-deficient mice\",\n      \"pmids\": [\"12711593\", \"14617760\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Receptor mediating satellite-cell mitogenesis not defined\", \"Cell type generating iNOS-dependent NO not pinpointed\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Resolved the bifurcation of TNF-alpha-induced caspase-8 activation into a c-FLIP-loss/RIPK1-independent route and a cIAP1/2-degradation/CYLD-dependent RIPK1–FADD–caspase-8 complex, and linked TNFR1 to mitochondrial apoptosis.\",\n      \"evidence\": \"Orthogonal genetic/pharmacological dissection of cIAP1/2, RIPK1, CYLD, c-FLIP; mitochondrial function and cytochrome c release assays with receptor blockade\",\n      \"pmids\": [\"18485876\", \"25492727\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Switch determinants between apoptosis and necroptosis not fully defined\", \"Mitochondrial study limited to a single lab/neuronal model\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Defined the transmembrane TNF-alpha biology, establishing it as a bidirectional signaling molecule and confirming ADAM17/TACE as the sheddase generating soluble TNF.\",\n      \"evidence\": \"Review of transmembrane vs soluble construct signaling and metalloprotease cleavage studies\",\n      \"pmids\": [\"20194223\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Reverse-signaling intracellular effectors not enumerated\", \"Review-level synthesis rather than single primary experiment\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Separated RIPK1 scaffold from kinase functions in vivo, showing the scaffold protects hepatocytes from TNF-driven apoptosis while kinase activity drives necrosis.\",\n      \"evidence\": \"Conditional Ripk1 knockout and kinase-dead knock-in mice in ConA hepatitis\",\n      \"pmids\": [\"27831558\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Substrate landscape of RIPK1 kinase activity not mapped\", \"Tissue specificity beyond liver untested\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Connected TNF shedding to disease via iRhom2-controlled ADAM17 activity and revealed transmembrane TNF reverse signaling as a driver of chemoresistance.\",\n      \"evidence\": \"iRhom2-knockout lupus-prone mice with transcriptome profiling; NTF domain mutants and xenografts for tmTNF reverse signaling\",\n      \"pmids\": [\"29369823\", \"29559745\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct intracellular partners of the tmTNF intracellular domain not identified\", \"iRhom2 specificity for TNF versus other substrates not exhaustive\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Linked TNF-alpha to bone resorption through direct osteocyte RANKL induction and identified cortistatin as a competitive antagonist at both receptors.\",\n      \"evidence\": \"Primary osteocyte/osteoclast co-culture with MAPK inhibitors and in vivo calvarial assays; reciprocal binding assays and receptor-knockout OA models\",\n      \"pmids\": [\"31921183\", \"30826358\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Relative receptor contribution to RANKL induction not parsed\", \"Cortistatin binding stoichiometry/affinity not quantified\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Expanded TNF-alpha's transcriptional reach by identifying MOF-driven H4K16 acetylation as an NF-κB coactivation mechanism and JNK-AP-1-RUNX1 as a distinct endothelial circuit.\",\n      \"evidence\": \"Myeloid-specific Mof-knockout mice with ChIP and etanercept rescue; pathway-inhibitor dissection in retinal endothelial cells\",\n      \"pmids\": [\"32069267\", \"33135824\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Generality of MOF coactivation across inflammatory contexts untested\", \"JNK-AP-1-RUNX1 loop shown by inhibitors only, single lab\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How cellular context selects among TNF-alpha's divergent outputs — NF-κB survival, apoptosis, necroptosis, regeneration, and metabolic disruption — through a shared receptor set remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unifying quantitative model of TNFR1 versus TNFR2 output selection\", \"Structural basis of differential receptor complex assembly not defined\", \"Determinants partitioning the RIPK1 complex toward apoptosis versus necroptosis incompletely mapped\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [1, 2, 6]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [0, 2, 17]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [8, 25]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [2, 3, 13]},\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [3, 4]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 9, 8]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [0, 15, 17, 26]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [11, 27]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [3, 4, 12]}\n    ],\n    \"complexes\": [\n      \"RIPK1-FADD-caspase-8 complex\"\n    ],\n    \"partners\": [\n      \"TNFRSF1A\",\n      \"TNFRSF1B\",\n      \"ADAM17\",\n      \"RHBDF2\",\n      \"BRE\",\n      \"RIPK1\",\n      \"CST\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}